Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
(NASDAQ: ROIV) Delayed: 36.20 -0.08 (0.22%)
Previous Close $36.28    52 Week High $ 
Open $36.13    52 Week Low $ 
Day High $36.49    P/E N/A 
Day Low $35.87    EPS $ 
Volume 4,527,335